Kiniksa Pharmaceuticals, Ltd. Provides Revenue Guidance for 2023
July 25, 2023 at 07:40 am EDT
Share
Kiniksa Pharmaceuticals, Ltd. provided revenue guidance for 2023. Kiniksa now expects 2023 ARCALYST net product revenue of between $220 million and $230 million compared to prior guidance of between $200 million and $215 million.
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Companyâs ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Companyâs Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
KINIKSA PHARMACEUTICALS, LTD. 
